EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Young Nam Kwon, Boram Kim, Jun-Soon Kim, Kyung Seok Park, Da-Young Seo, Hyunjin Kim, Eun-Jae Lee, Young-Min Lim, Hyunjin Ju, Yeon Hak Chung, Ju-Hong Min, Tai-Seung Nam und 21 weitere

JAMA Neurology · 01.10.2024 · 81 (10) · 1073

DOI: 10.1001/jamaneurol.2024.2811 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Neurology, erschienen am 01.10.2024. Verfasst von Young Nam Kwon und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Myelin-Oligodendrocyte Glycoprotein. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance A proportion of people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) have a relapsing disease course and persistent anti–myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) seropositivity. Few studies have investigated whether treatment of the first MOGAD attack is associated with the long-term disease course and/or MOG-IgG seronegative conversion.

Objective

To investigate the association of time to treat the first acute MOGAD attack with relapse risk and MOG-IgG serostatus. Design, Setting, and Participants This was a retrospective, nationwide, multicenter cohort study involving 14 secondary or tertiary hospitals in South Korea between November 2009 and August 2023. People with adult-onset MOGAD, who either had a relapse or were followed up for more than 12 months after disease onset and had a detailed medical record of their first attack, were included. Individuals were excluded for adolescent-onset MOGAD or short disease duration. Exposures Patients were categorized based on the time to treat the first acute MOGAD attack: early (<5 days), intermediate (5-14 days), and late (not treated within 14 days). Main Outcomes and Measures A multivariable analysis for clinical and treatment factors associated with relapsing disease course and/or MOG-IgG seronegative conversion. Further subgroup analyses were conducted among those without long-term nonsteroidal immunosuppressant (NSIS) maintenance treatment.

Results

Among the 315 individuals screened, 75 were excluded. A total of 240 patients (median [IQR] age at onset, 40.4 [28.8-56.1] years; 125 female [52.1%]) with median (IQR) disease duration of 3.07 (1.95-6.15) years were included. A total of 110 of 240 patients (45.8%) relapsed after a median (IQR) of 0.45 (0.18-1.68) years, and 29 of 116 patients (25.0%) experienced a conversion to seronegative MOG-IgG. Both the time to treatment of the first MOGAD attack (late vs early: adjusted hazard ratio [aHR], 2.64; 95% CI, 1.43-4.84; P = .002; intermediate vs early: aHR, 2.02; 95% CI, 1.10-3.74; P = .02) and NSIS maintenance treatment (aHR, 0.24; 95% CI, 0.14-0.42; P < .001) were independently associated with the risk of relapse. In a subgroup without NSIS maintenance, the time to treat of the first MOGAD attack was still associated with higher risk of relapse (late vs early: aHR, 3.51; 95% CI, 1.64-7.50; P = .001; intermediate vs early: aHR, 2.68; 95% CI, 1.23-5.85; P = .01). Lastly, the time to treat of the first MOGAD attack was also associated with MOG-IgG seronegative conversion (early vs late: adjusted odds ratio, 7.04; 95% CI, 1.58-31.41; P = .01), whereas NSIS maintenance treatment was not. Conclusions and Relevance Results of this cohort study suggest that early treatment of the first acute MOGAD attack was associated with a reduction in the proportion of relapsing disease course and an increase in the likelihood of MOG-IgG seronegative conversion. These data suggest that timing of acute phase treatment for the first MOGAD attack can be associated with the long-term prognosis and autoimmune status of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelin-Oligodendrocyte GlycoproteinHumansFemaleMaleAdultMiddle AgedRetrospective StudiesRecurrenceCohort StudiesAutoantibodiesTime-to-TreatmentImmunoglobulin GRepublic of KoreaDemyelinating Autoimmune Diseases, CNS

Substanzen

Myelin-Oligodendrocyte GlycoproteinAutoantibodiesImmunoglobulin GMOG protein, human

Autor:innen und Institutionen

  • Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Biomedical Research Institute, Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Gyeonggi-do, Republic of Korea.
  • Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Kwon, Y. N., Kim, B., Kim, J. S., Park, K. S., Seo, D. Y., Kim, H., Lee, E. J., Lim, Y. M., Ju, H., Chung, Y. H., Min, J. H., Nam, T. S., Kim, S., Sohn, E., Shin, K. J., Seok, J. M., Kim, S., Bae, J. S., Lee, S., …, & Kim, S. M. (2024). Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurology, 81(10), 1073. https://doi.org/10.1001/jamaneurol.2024.2811

Vancouver

Kwon YN, Kim B, Kim JS, Park KS, Seo DY, Kim H, et al. Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurology. 2024;81(10):1073. doi:10.1001/jamaneurol.2024.2811

BibTeX
@article{Kwon2024,
  author = {Kwon, Young Nam and Kim, Boram and Kim, Jun-Soon and Park, Kyung Seok and Seo, Da-Young and Kim, Hyunjin and Lee, Eun-Jae and Lim, Young-Min and Ju, Hyunjin and Chung, Yeon Hak and Min, Ju-Hong and Nam, Tai-Seung and Kim, Sooyoung and Sohn, Eunhee and Shin, Kyong Jin and Seok, Jin Myoung and Kim, Sunyoung and Bae, Jong Seok and Lee, Sukyoon and Oh, Seong-Il and Jung, Yu Jin and Park, Jinseok and Kim, Seung Hyun and Kim, Ki Hoon and Kim, Ho Jin and Jung, Jae Ho and Kim, Seong-Joon and Kim, Seung Woo and Jang, Myoung-Jin and Sung, Jung-Joon and Waters, Patrick and Shin, Ha Young and Kim, Sung-Min},
  title = {Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease},
  journal = {JAMA Neurology},
  year = {2024},
  volume = {81},
  number = {10},
  pages = {1073},
  doi = {10.1001/jamaneurol.2024.2811}
}
Kostenlos starten →